CA2441832A1 - Proteines secretees humaines - Google Patents

Proteines secretees humaines Download PDF

Info

Publication number
CA2441832A1
CA2441832A1 CA002441832A CA2441832A CA2441832A1 CA 2441832 A1 CA2441832 A1 CA 2441832A1 CA 002441832 A CA002441832 A CA 002441832A CA 2441832 A CA2441832 A CA 2441832A CA 2441832 A1 CA2441832 A1 CA 2441832A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
referenced
fragment
cdna clone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002441832A
Other languages
English (en)
Inventor
Craig A. Rosen
Steven M. Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2441832A1 publication Critical patent/CA2441832A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des polypeptides sécrétés humains, ainsi que des molécules d'acides nucléiques isolés codant lesdits polypeptides, servant à diagnostiquer et à traiter des maladies et des affections auto-immunes. L'invention concerne également des anticorps qui fixent ces polypeptides, ainsi que des vecteurs, des cellules hôtes, des méthodes de recombinaison et de synthèse pour produire lesdits polynucléotides, polypeptides et/ou anticorps. L'invention concerne en outre des méthodes de criblage servant à identifier des agonistes et des antagonistes des polynucléotides et polypeptides de l'invention. Elle concerne enfin des méthodes et des compositions servant à inhiber ou stimuler la production et la fonction des polypeptides de l'invention.
CA002441832A 2001-03-21 2002-03-19 Proteines secretees humaines Abandoned CA2441832A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US60/277,340 2001-03-21
US30617101P 2001-07-19 2001-07-19
US60/306,171 2001-07-19
US33128701P 2001-11-13 2001-11-13
US60/331,287 2001-11-13
PCT/US2002/008278 WO2002102994A2 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines

Publications (1)

Publication Number Publication Date
CA2441832A1 true CA2441832A1 (fr) 2002-12-27

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
CA002441702A Abandoned CA2441702A1 (fr) 2001-03-21 2002-03-19 Proteines secretees par l'homme
CA002441840A Abandoned CA2441840A1 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
CA002441832A Abandoned CA2441832A1 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
CA002441397A Abandoned CA2441397A1 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees
CA002441417A Abandoned CA2441417A1 (fr) 2001-03-21 2002-03-19 Proteines secretees par les humains
CA002441755A Abandoned CA2441755A1 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
CA002441416A Abandoned CA2441416A1 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA002441702A Abandoned CA2441702A1 (fr) 2001-03-21 2002-03-19 Proteines secretees par l'homme
CA002441840A Abandoned CA2441840A1 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines

Family Applications After (4)

Application Number Title Priority Date Filing Date
CA002441397A Abandoned CA2441397A1 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees
CA002441417A Abandoned CA2441417A1 (fr) 2001-03-21 2002-03-19 Proteines secretees par les humains
CA002441755A Abandoned CA2441755A1 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
CA002441416A Abandoned CA2441416A1 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees

Country Status (4)

Country Link
EP (7) EP1379132A4 (fr)
AU (6) AU2002363296A1 (fr)
CA (7) CA2441702A1 (fr)
WO (7) WO2002102994A2 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
EP1000084A4 (fr) 1997-07-08 2003-03-26 Human Genome Sciences Inc 123 proteines humaines secretees
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EE200100372A (et) 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A3 (fr) * 2000-07-25 2006-11-02 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP1364021A2 (fr) 2000-10-31 2003-11-26 Diadexus, Inc. Compositions et methodes associees a des genes et a des proteines specifiques du colon
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
EP1573024A4 (fr) * 2001-04-10 2007-08-29 Agensys Inc Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP2287186B1 (fr) 2001-09-06 2014-12-31 Agensys, Inc. Acide nucléique et protéine corréspondante designés par STEAP-1 utiles dans le traitement et la détection du cancer
WO2003033727A1 (fr) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Procede de criblage d'un inhibiteur de la mort cellulaire
EP1997512B1 (fr) 2002-04-09 2013-12-04 Biogen Idec MA Inc. Procédés de traitement de conditions associées à TWEAK
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (fr) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
ES2339710T5 (es) 2003-09-23 2017-10-05 University Of North Carolina At Chapel Hill Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
PL2189523T3 (pl) * 2003-10-14 2012-05-31 Baxalta Inc Polipeptyd przekształcający epoksyd witaminy K VKORC1, obiekt działania leczniczego kumaryny i jej pochodnych
EP1714154A2 (fr) * 2004-02-03 2006-10-25 Bayer HealthCare AG Agents diagnostiques et therapeutiques pour des maladies associes a la glutamate carboxypeptidase (pgcp) plasmatique
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
MXPA06012187A (es) 2004-04-22 2007-03-28 Agensys Inc Anticuerpos y moleculas derivadas de estas que se enlazan a las proteinas steap-1.
US8759305B2 (en) * 2004-09-01 2014-06-24 Dynavax Technologies Corporation Methods and compositions for inhibition of innate immune responses and autoimmunity
CA2579705A1 (fr) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Methode de diagnostic et/ou de prediction du developpement d'une affection allergique
CA2579349A1 (fr) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents pour le traitement ou la prevention d'une affection allergique
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
MX349285B (es) 2005-02-28 2017-07-20 Baxalta Inc Co-expresion recombinante de reductasa de epoxido de vitamina k subunidad 1 para mejorar la expresion de proteina dependiente de vitamina k.
EP1861499A4 (fr) 2005-03-15 2008-09-03 Univ North Carolina Procédés et compositions pour la production de protéines actives dépendantes de la vitamine k
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
WO2006138219A2 (fr) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
GB2445882B (en) * 2005-09-01 2011-02-23 Florey Howard Inst Prophylactic and therapeutic agents and compositions and uses therefor and methods for determining the presence or severity of neuronal damage
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US8436147B2 (en) 2006-10-27 2013-05-07 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2083864A4 (fr) 2006-11-07 2010-12-08 Merck Sharp & Dohme Antagonistes de pcsk9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2142217B1 (fr) * 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Procédé de détection de pcsk9 secrétée, autogénérée
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2209896B1 (fr) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Procédés et compositions pour inhiber les réponses immunitaires et l'auto-immunité
US8017573B2 (en) * 2007-11-30 2011-09-13 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
JP2013509191A (ja) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ａｘ１およびａｘ１８９ｐｃｓｋ９アンタゴニストおよびバリアント
CN102639150A (zh) 2009-10-30 2012-08-15 默沙东公司 Ax213和ax132 pcsk9拮抗剂和变体
EP2582398B1 (fr) 2010-06-16 2016-04-13 Dynavax Technologies Corporation Méthodes et traitements a l'aide d'inhibiteurs de tlr7 et/ tlr9
US8871737B2 (en) 2010-09-22 2014-10-28 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012088222A2 (fr) 2010-12-21 2012-06-28 The University Of North Carolina At Chapel Hill Procédés et compositions pour la production de protéines actives dépendantes de la vitamine k
WO2013096680A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucléotide phosphorothioate substitués
EP2828277A1 (fr) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Formes solides d'un promédicament nucléotidique thiophosphoramidate
WO2013142157A1 (fr) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
CA3048479A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Edition genique de pcsk9
BR112019018767A2 (pt) 2017-04-03 2020-05-05 Hoffmann La Roche anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção
CN110719968A (zh) * 2017-06-22 2020-01-21 宝洁公司 包括水溶性层和气相沉积无机涂层的膜
CN110709174A (zh) 2017-06-22 2020-01-17 宝洁公司 包括水溶性层和气相沉积有机涂层的膜
US20230158174A1 (en) 2020-04-09 2023-05-25 Verve Therapeutics, Inc. Chemically modified guide rnas for genome editing with cas9

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
WO2000004140A1 (fr) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 proteines humaines secretees
WO2002026931A2 (fr) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 proteines humaines secretees
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Also Published As

Publication number Publication date
EP1379264A1 (fr) 2004-01-14
WO2002102994A2 (fr) 2002-12-27
EP1379132A2 (fr) 2004-01-14
EP1423134A2 (fr) 2004-06-02
EP1414845A2 (fr) 2004-05-06
EP1381622A2 (fr) 2004-01-21
CA2441702A1 (fr) 2002-12-27
WO2003004622A2 (fr) 2003-01-16
AU2002332391A1 (en) 2003-01-02
WO2002095010A2 (fr) 2002-11-28
WO2002076488A1 (fr) 2002-10-03
CA2441417A1 (fr) 2002-11-14
WO2002090526A2 (fr) 2002-11-14
WO2002102994A3 (fr) 2003-07-24
WO2002102993A3 (fr) 2004-03-25
EP1390390A2 (fr) 2004-02-25
EP1414845A4 (fr) 2009-07-08
CA2441416A1 (fr) 2003-01-16
AU2002326293A1 (en) 2003-01-02
WO2003004622A3 (fr) 2004-02-19
CA2441840A1 (fr) 2002-11-28
AU2002324424A1 (en) 2002-12-03
EP1404702A2 (fr) 2004-04-07
EP1379264A4 (fr) 2009-07-08
EP1390390A4 (fr) 2009-07-08
WO2003038063A2 (fr) 2003-05-08
WO2002102993A2 (fr) 2002-12-27
EP1379132A4 (fr) 2009-07-01
EP1404702A4 (fr) 2009-07-08
AU2002354719A1 (en) 2003-01-21
WO2002095010A3 (fr) 2004-02-12
WO2003038063A3 (fr) 2003-12-11
CA2441397A1 (fr) 2002-10-03
WO2002090526A3 (fr) 2003-10-30
AU2002363296A1 (en) 2003-05-12
AU2002320013A1 (en) 2002-11-18
CA2441755A1 (fr) 2003-05-08

Similar Documents

Publication Publication Date Title
CA2441832A1 (fr) Proteines secretees humaines
CA2442777A1 (fr) Proteines secretees par l'etre humain
CA2393616A1 (fr) Acides nucleiques, proteines et anticorps
US6380362B1 (en) Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
EP0428602B1 (fr) Polypetides et adn les encodant
Crovella et al. Primate β-defensins-structure, function and evolution
CA2395885A1 (fr) Acides nucleiques, proteines et anticorps
CA2283678A1 (fr) 28 proteines secretees par l'homme
JP2001509030A (ja) Ｆｃレセプターおよびポリペプチド
JP2002502600A (ja) ヒトセリンプロテアーゼおよびセルピンポリペプチド
EP0998490A2 (fr) Proteines secretees et polynucleotides les codant
EP1379648A1 (fr) Adn complementaires humains pleine longueur codant des proteines potentiellement secretees
JP2003525566A (ja) １２５個のヒト分泌タンパク質
WO1998055614A2 (fr) Proteines secretees et polynucleotides codant ces proteines
EP1283214B1 (fr) Nouvelles collectines
CA2324492A1 (fr) Proteines secretees et polynucleotides les codant
EP0240224A2 (fr) Analogue d'alpha interféron
JP4233757B2 (ja) 尋常よもぎ（Ａｒｔｅｍｉｓｉａ ｖｕｌｇａｒｉｓ（ｍｕｇｗｏｒｔ））花粉の組換え主要アレルゲン
JPH10504456A (ja) Ｃ５ａレセプターをコードするポリヌクレオチド
AU2001235625B2 (en) Partners of PTB1 domain of FE65, preparation and uses
EP0971954A2 (fr) Proteines secretees et polynucleotides les codant
JP3379952B2 (ja) オーレオバシジン感受性遺伝子
CA2318303A1 (fr) Proteines secretees et polynucleotides les codant
US20040110194A1 (en) Genes regulated by human cytokines
CA2291485A1 (fr) Proteines secretees et polynucleotides codant ces proteines

Legal Events

Date Code Title Description
FZDE Dead